Abstract: Palladium-substituted Bacteriochlorophyll derivatives of formula (I), wherein A represents OH, OR1, —O—(CH2)n—Y, —S—(CH2)n—Y, —NH—(CH2)n—Y, —O—(CH2)2—NH2, —O—(CH2)2—OH, —NH—(CH2)n—+N o, X—, —NH0(CH2)2—NH═BOC or —N—(CH2—CH═CH2)2; wherein R1 represents Na+, K+, (Ca2+)0, 5, (Mg2+)0, 5, Li+, NH4+, NH3—C(CH2OH)3 +NH3—CH2—(CHOH)4—CH2OH, +NH2(CH3)—CH2—(CHOH)4—CH2OH or +N(CN′H2n′+1)4; R2 represents H, OH or COOR4, wherein R4 is C1-C12 alkyl or C3-C12 cycloalkl; R3 represents H, OH or C1-C12 alkyl or alkoxy; n is 1, 2, 3, 4, 5 or 6, Y is —NR′1R′2R′3, X-wherein R′1, R′2 and R′3 independently from each other represent —CH3 or —C2H5; X is F, Cl, Br or 1, n′ is 1, 2, 3 or 4 and their oxidized forms, are u

Abstract: A topical skin composition that includes a complex containing an effective amount of selected components to provide a defense against the various pathway mechanisms of reactive oxygen species. In addition, a method for the treatment of the skin is provided. The composition and method are directed to the prevention of the adverse or detrimental effects of reactive oxygen species.

Abstract: The present invention relates to metal salts of 3-methyl-chromane or thiochromane derivatives, stereoisomers or hydrates thereof, and an anti-estrogenic pharmaceutical composition which comprises the above compound as an active component and exhibits a highly improved solubility.

Abstract: A compound with formula (I) where R10 is a therapeutically removable nitrogen protecting group; R2 and R3 are independently selected from: H, R, OH, OR, ═O, ═CH—R, ═CH2, CH2—CO2R, CH2—CO2H, CH2—SO2R, O—SO2—R, CO2R, COR and CN; R6, R7 and R9 are independently selected from H, R, OH, OR, halo, amino, nitro, Me3Sn; X is S, O or NH; R11 is either H or R; and where there is optionally a double bond between C1 and C2 or C2 and C3; and R8 is selected from H, R, OH, OR, halo, amino, nitro, Me3Sn, or R7 and R8 together form a group —O—(CH2)p—O—, where p is 1 or 2. Such compounds may be used in methods of ADEPT, GDEPT, NPEPT or PDT.

Abstract: A novel approach to fight bacterial growth on and attachment to medical devices/implants is described. This approach reduces the necessity of the painful and complicated replacement of the medical devices that frequently need to remain in the body for periods of time longer than is recommended using a traditionally sterilized device. Several methods are described to kill bacteria that have attached to the surface of medical devices. Long term use is then possible with those medical devices. Furthermore a medical device is described under this method that has a photosensitizing compound affixed to or near the device surface with means to periodically activate the compound by suitable illumination.

Abstract: The invention relates to the selection and treatment of subjects afflicted with occult choroidal neovascular lesions, including subjects with age-related macular degeneration, by use of photo dynamic therapy (PDT).

Abstract: Premature vascular senescence is reversed or prevented in tissue or cells by contacting the tissue or cells with a peroxynitrite scavenger or peroxynitrite formation inhibitor that does not diminish nitric oxide synthesis. This finds application in treatment of patients with a disorder associated with elevated levels of advanced glycation end products in blood or tissue, e.g., patients with end stage renal disease or poorly controlled diabetes, and in contacting vascular tissue or cells ex vivo to prevent occurrence of premature senescence.

Abstract: A method for coating a substance with a coating comprising a mixture of a cellulose ether and a metal chlorophyllin chelate is disclosed. The coating can be used for improving stability of the substance and reducing objectionable tastes and/or odors in the substance.

Abstract: A system and a method using photodynamic therapy for treatment of epithelial diseases are provided, wherein the photosensitizers used have enhanced selectivity for the affected region so that the treatment has reduced or no side effects. Selectivity is achieved by avoiding systemic application of the photosensitizer and by topically applying the photosensitizers with certain carriers. Compositions of hydrophilic medical or cosmetic carriers like ointments, creams or lotions can be used. Hydrophobic photosensitizers such as bacteriopheophorbide and its derivatives are preferred because of their ability to penetrate tissue and to distribute evenly, as well as their low threshold of phototoxicity. After the phototoxic sensitizer has been administered to the afflicted tissue, the tissue is irradiated with an appropriate radiation source, such as sunlight or a radiation source emitting a defined wavelength like a diode laser.

Abstract: The formation of free radicals is enhanced with photodynamic agents, sonodynamic agents, and systems and therapies utilizing ultrasound by subjecting the agent to light waves or sound waves in the presence of a metal, a reductant, or a chelate, or mixtures thereof.

Abstract: The invention provides methods for treating cancer and compounds that are useful for the treatment of tumors, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates useful for preparing the compounds.

Abstract: Novel derivatives of metallotexaphyrins are prepared by modifying the apical ligands associated with the central metal component of a metallotexaphyrin.

Abstract: The present invention provides the porphyrin compound having nitroimidazole in the molecule, which is used for diagnosis and/or treatment of cancer in magnetic resonance imaging (MRI) and/or radiotherapy as well as for DDS therapy. The porphyrin compound of the present invention shows no phototoxicity, and represented by the following formula: [wherein, R1 and R2 are —CH═CH2 or —CH(CH3)—OH, —CH(CH3)—O—(CH2)n—NH—Ra; R3 is hydrogen atom or —CO—(CH2)m—COOH; and M is transition metal of Mn, Fe, Co or Cu], (in which, Ra is hydrogen atom or the group represented by the following formula: n and m are the integer 2 or 3), or a pharmaceutically acceptable salt thereof.

Abstract: The present invention is directed to novel photosensitive compounds that can be replicated with great certainty and provide applications for photodynamic therapy.

Abstract: The present invention relates, in general, to a method of modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and compositions suitable for use in such methods.

Abstract: This invention provides a soluble inclusion complex formed of a water-insoluble lipophilic compound and an amphiphilic polymer and which demonstrated improved solubility and stability. The lipophilic compound within the inclusion complex may consist of pharmaceutical compounds, food additives, cosmetics, agricultural products and veterinary products. The invention also provides novel methods for preparing the inclusion complex, as well as a novel chemical reactor for forming the inclusion complex.

Abstract: This invention provides a novel class of substituted macrocyclic metallic complexes. The complexes are useful as peroxynitrite decomposition catalysts. Pharmaceutical compositions, and methods of making and using the compounds, or a pharmaceutically acceptable salt, hydrate, prodrug, or mixture thereof are also described.

Abstract: A series of novel positively-charged porphyrins is disclosed which exhibit a markedly increased efficiency in photosensitizing both Gram-positive and Gram-negative bacteria to the action of visible light, causing death to such bacteria when present at much lower concentrations and much shorter irradiation times than those porphyrins taught in the prior art. These porphyrins are characterized by the presence of up to four positive charges in the peripheral substituents and at least one hydrophobic tail comprising between 6 and 22 carbons inclusive, originating at one or more of the charged sites.

Abstract: The present invention relates, in general, to cancer therapy, and, in particular, to a method of preventing or treating cancer using low molecular weight antioxidants (e.g., mimetics of superoxide dismutase (SOD)) as the active agent or as a chemo- and/or radio-protectant. The invention also relates to compounds and compositions suitable for use in such a method.

Abstract: The invention provides medicaments comprising an oenothein, including topical formulations for use as free radical scavengers, or to treat irritation, or to treat inflammation. The oenothein for use in such formulations, such as oenothein-A or oenothein-B, may be purified from natural sources, such as plant material (e.g. Epilobium angustifolium).

Abstract: Low molecular weight mimics of superoxide dismutase (SOD) represented by the formula: wherein R, R′, R1, R′1, R2, R′2, R3, R′3, R4, R′4, R5, R′5, R6, R′6, R7, R′7, R8, R′8, R9, and R′9, M, X, Y, Z and n are as defined herein, useful as therapeutic agents for inflammatory disease states and disorders, ischemic/reperfusion injury, stroke, atherosclerosis, and all other conditions of oxidant-induced tissue damage or injury.

Abstract: The present invention discloses dye-sulfenate derivatives and their bioconjugates for dual phototherapy of tumors and other lesions. The compounds of the present invention may contain either a mixture of Type 1 and Type 2 agents or a single entity that integrates both units in the same molecules. The compounds are designed to produce both Type 1 and Type 2 phototherapeutic effect at once using dual wavelength light source that will produce singlet oxygen and free radicals at the lesion of interest.

Abstract: The present invention relates, in one embodiment, to a method of preventing or treating diabetes using low molecular weight antioxidants. In a further embodiment, the invention relates to a method of protecting and/or enhancing viability of cells/tissues/organs during isolation (harvesting), preservation, expansion and/or transplantation. In yet another embodiment, the present invention relates to a method of inducing immune tolerance. The invention also relates to compounds and compositions suitable for use in such methods.

Abstract: Disclosed are compounds which are conjugates of (a) a moiety capable of localizing in the cells of a tumor or atheroma and (b) a moiety capable of catalyzing the production of reactive oxygen species from a cellular metabolite. The disclosed compounds which are useful for treating atheroma, tumors and other neoplastic tissue.

Abstract: Phthalocyanine compounds of the formulas I and II: wherein X1-8 are each halogen and R1-8 are each independently halogen or an anti-stacking moiety; and [MxLySz]Cw  (II) wherein M is a metal, L is an anion of a phthalocyanine compound of formula I as defined above, S is an organic or inorganic ligand, C is a counterion, x and y are numbers greater than zero, and z and w are numbers zero or greater, are disclosed. Pharmaceutical compositions comprising the compounds and methods of using the compounds, for example for treatment of cancer, are also disclosed.

Abstract: The present invention provides the porphyrin compound which is used for photodynamic diagnosis and/or treatment for animals, and the photodynamic diagnostic and/or therapeutic agent for animals.

Abstract: Vanadium (IV) complexes containing a substituted or unsubstituted catecholate ligand, and the spermicidal activity of such compounds. Preferred compounds are vanadocene (IV) complexes containing alkyl substituted catecholate ligands.

Abstract: The present invention discloses novel photoactive compounds that may be crosslinked to target substrates. Methods for the preparation and use of the compounds, as well as compositions comprising them, are also disclosed.

Abstract: The use of transition metal complexes in the treatment of septic shock, in particular the hypotension associated therewith and pharmaceutical formulations comprising such complexes are disclosed. The use of such transition metal complexes in the treatment of other conditions caused by pathological NO production are also disclosed.

Abstract: The invention relates to photodynamic therapy (PDT) is used in combination with apoptosis-inducing agents to destroy target cells and tissues. Benefits of such combinations include 1) the ability to use lower doses of photosensitizers and/or light; 2) the ability to use lower doses of apoptosis-inducing agents; and 3) the ability to use apoptosis-inducing agents against target tissues which are otherwise insensitive to the apoptosis-inducing agents.

Abstract: Effective treatment of tumors, especially carcinomas, can be achieved by administering to man a photochemotherapeutic agent containing as an active ingredient a compound showing maximum absorption in the wavelength region of 800 to 1,200 nm, and then applying light rays of a wavelength of 800 to 1,200 nm.

Abstract: Purpurin-carbohydrate conjugates and their method of preparation and use for treatment of cancer cells.

Abstract: The present invention relates to modulating inflammation, or improving hemodynamic function, associated with trauma, such as that caused by surgery, through the administration of metal complexes, such as ruthenium nitric oxide scavengers. Further, the present invention relates to modulating matrix metalloproteinase activity also by administering such metal complexes. Modulation of the trauma or the metalloproteinase activity reduces tissue damage or causes a protective effect against organ damage.

Abstract: Compositions and methods for promoting a healthy cardiovascular system and enhancing healthy blood flow by gently removing toxic buildup from the arterial walls and dilating and strengthening the arterial walls, in a mammal. The compositions comprise calcium; magnesium; selenium; manganese; zinc; potassium; vitamin E; vitamin A; alpha-lipoic acid; Allium sativum extract; Afecicago satiia extract; Chondrus crispus extract; L-cysteine; L-glutamic acid; glycine; and glutathione.

Abstract: The present invention provides methods and formulations for optimizing the anti-cancer and anti-HIV activities of a camptothecin drug, including camptothecin and its related analogs including 9-aminocamptothecin and 9-nitrocamptothecin. The invention involves methodologies and formulations that limit human serum albumin-mediated reduction of the anti-cancer and anti-HIV effects of the camptothecins, and the methods and formulations provide combination therapies in which binding of the camptothecin agent to human serum albumin can be modulated by the administration of a competing agent that also binds human serum albumin. Reduced camptothecin drug binding to human serum albumin can result in elevated camptothecin free drug levels and thus improve the effectiveness of treatment regimens involving these drugs. Further agents such as methotrexate and AZT can also be used in cancer and HIV-positive patients employing camptothecin drugs.

Abstract: A method in which photodynamic therapy is employed to inhibit, stabilize or reduce occlusions within the cardiovascular system by utilizing light within the spectral region of approximately 390 to approximately 610 nm.

Abstract: Conjugate molecules which include photosensitizer compositions conjugated to non-antibody non-affinity pair targeting moieties and methods of making and using such conjugates are described.

Abstract: An improved method to treat conditions of the eye characterized by ocular neovascularization is provided in which patients are given and initial photodynamic therapy (PDT) treatment to destroy the neovasculature, and then are re-evaluated at least twice during the following 6 months, and retreated as necessary. Preferably, three retreatments are provided.

Abstract: Novel compounds of the following general formula or salts thereof. wherein Ring M is a heterocyclic ring having —N═C<, —CO—N< or —CS—N< as the partial structure —X{overscore (— — — — — — — — —)} Y<; Ra and Rb are bonded to each other to form Ring A, or they are the same or different and represent, independently, a hydrogen atom or a substituent on the Ring M; Ring A and Ring B represent, independently, an optionally substituted homocyclic or heterocyclic ring, and at least one of them is optionally substituted heterocyclic ring; Rng C is optionally substituted homocyclic or heterocyclic ring; Rng Z is an optionally substituted ring; and n represents an integer of from 1 to 6, or a salt thereof, which has an excellent tachykinin receptor antagonistic effect, and their production, and pharmaceutical compositions.

Abstract: The use of a pharmaceutical formulation in treating coronary arteriosclerosis and a two-component pharmaceutical formulation. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimithyl sulfoxide; a dye containing a chelated metal, such as hematoporphyrin; and an aromatic redox compound, such as benzoquinone.

Abstract: A composition comprising a C3-5-alkyl-1,2-benzisothiazolin-3-one and the metal complex of a cyclic thiohydroxamic acid such as the 2:1 zinc salt of either 3-hydroxy-4-methylthiazol-2(3H)-thione or 1-hydroxypyridine-2-thione.

Abstract: The invention provides hybrid pigments containing: (a) at least one benzimidazolone triphenodioxazine compound of the formula (I)  and (b) at least one pyrrolo-[3,4-c]-pyrrole compound, or (c) at least one thiazine-indigo compound, or (d) at least one quinacridone compound or (e) at least one copper phthalocyanine compound and a process for the preparation of such hybrid pigments and their use for the mass pigmentation of substrates, as colorants in electrophotographic toners and developers, in powders and powder coating materials, in ink-jet inks and in cosmetic compositions.

Abstract: Cobalt-porphyrin (Co-P) complexes for use as anti-obesity agents, and compositions and methods related thereto. The Co-P complexes exhibit reduced redox activity compared to cobalt mesoporphyrin (Co-MP) and cobalt protoporphyrin (Co-PP), which alleviates the deleterious effects associated with administration of Co-P associated with oxidative stress, particularly in the context of injection site toxicity.

Abstract: Concentrates of various classical biocides in a polyester carrier resin when incorporated into a substrate resin, preferably a polyolefin such as polypropylene or polyethylene, provide the substrate polymer which biocidal activity with superior resistance to discoloration (yellowing) than when the biocide is directly incorporated into the substrate polymer as a powder at the same total concentration.

Abstract: The likelihood of chlamydia infection can be prevented by the topical application of metallo-organic cobalt compounds according to the following formula to the cite of infection: wherein each A may be the same or different and is an alkyl group, a phenyl group or a substituted derivative of a phenyl group; each Y may be the same or different and is hydrogen, an unbranched alkyl group, a halide or a group having the structure wherein R is hydrogen, an alkoxide group, and alkyl group, or OH; each B may be the same or different and each is hydrogen or an alkyl group; each X may be the same or different and each is a water soluble group having weak to intermediate ligand filed strength; and Z− is a soluble, pharmaceutically acceptable negative ion. Metallo-organic cobalt compounds may also be used to disinfect liquids which contain chlamydia.

Abstract: Compositions comprising microaggregates containing hydrophobic drugs, as well as methods for their production, are described. Such microaggregates may include micelle structures or combinations thereof with liposomes, and constitute an effective delivery vehicle for a hydrophobic agent. Methods for microaggregate production include the use of preferred lipid compounds and processing conditions favoring the production of small aggregates for improved filter sterilization.

Abstract: An anti-cancer substance has a porphyrin-like molecule conjugated to an anti-cancer drug. In one embodiment, the porphyrin-like molecule is conjugated directly to an anti-cancer drug. In a second embodiment, the porphyrin-like molecule is conjugated to a first end of a peptide chain, while a second end of the peptide chain is conjugated to the anti-cancer drug. The peptide chain is designed to be cleaved under physiological conditions surrounding the tumor. In the preferred embodiment, the peptide chain functions as a protease inhibitor once it has been cleaved.

Abstract: Vanadium (IV) complexes containing a substituted or unsubstituted catecholate ligand, and the spermicidal activity of such compounds. Preferred compounds are vanadocene (IV) complexes containing alkyl substituted catecholate ligands.

Abstract: The invention provides methods and compositions for promoting neural cell growth and/or regeneration. The general methods involve contacting with an activator of a cyclic nucleotide dependent protein kinase a neural cell subject to growth repulsion mediated by a neural cell growth repulsion factor. The activator may comprise a direct or an indirect activator of the protein kinase; the repulsion factor typically comprises one or more natural, endogenous proteins mediating localized repulsion or inhibition of neural cell growth; and the target cells are generally vertebrate neurons, typically injured mammalian neurons. The subject compositions include mixtures comprising a neural cell, an activator of a cyclic nucleotide dependent protein kinase and a neural cell growth repulsion factor.

Abstract: As a novel photochemotherapeutical method for the treatment or prevention of an auto-immune disease, there is provided a method for treating an auto-immune disease, which comprises administering to the patient mono-L-aspartyl chlorin e6 or mono-L-glutamyl chlorin e6 or a pharmacologically acceptable salt thereof, followed by subjecting the blood vessel blood of the patient containing the administered compound to exposure with an ultraviolet ray or a laser light, thereby to excite said compound photochemically. This method is effective to decrease the level of auto-antibody in the blood of the patient and is also of high safety.